Posterior segment toxicity after gemcitabine and docetaxel chemotherapy

Optometry and Vision Science

Volumn 92, Issue 5, 2015, Pages e110-e113

  Kord Valeshabad, Ali ^a   Mieler, William F ^a   Setlur, Vikram ^a   Thomas, Merina ^a   Shahidi, Mahnaz ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

chemotherapy; docetaxel; gemcitabine; retina; uveal effusion

Indexed keywords

CHEMOTHERAPY; COHERENT LIGHT; OPHTHALMOLOGY; OPTICAL TOMOGRAPHY; ULTRASONIC APPLICATIONS; ULTRASONOGRAPHY; VISION;

COMBINATION CHEMOTHERAPY; COMBINATION THERAPY; DOCETAXEL; GEMCITABINE; RETINA; SLIT LAMP EXAMINATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHIES; UVEAL EFFUSION;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DOCETAXEL; GEMCITABINE; TAXOID;

AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CASE REPORT; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; HUMAN; NEOPLASMS, UNKNOWN PRIMARY; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PHOTORECEPTOR CELL; PROCEDURES; SARCOMA; UVEAL DISEASES; VISION DISORDERS; VISUAL ACUITY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; PHOTORECEPTOR CELLS, VERTEBRATE; SARCOMA; TAXOIDS; TOMOGRAPHY, OPTICAL COHERENCE; UVEAL DISEASES; VISION DISORDERS; VISUAL ACUITY;

EID: 84929463378     PISSN: 10405488     EISSN: 15389235     Source Type: Journal    
DOI: 10.1097/OPX.0000000000000571     Document Type: Article

References (17)

1. Singh P, Singh A. Ocular adverse effects of anti-cancer chemotherapy. J Cancer Therapeut Res 2012;1:1-7.
2. Schmid KE, Kornek GV, Scheithauer W, Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 2006;51:19-40.
3. Liu CY, Francis JH, Brodie SE, Marr B, Pulido JS, Marmor MF, Abramson DH. Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina 2014;34:1261-80.
4. Chen TC, Chao CW, Sorkin JA. Topiramate induced myopic shift and angle closure glaucoma. Br J Ophthalmol 2003;87:648-9.
5. Takusagawa HL, Hunter RS, Jue A, Pasquale LR, Chen TC. Bilateral uveal effusion and angle-closure glaucoma associated with bupropion use. Arch Ophthalmol 2012;130:120-2.
6. Lauer AK, Wobig JL, Shults WT, Neuwelt EA, Wilson MW. Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy. Am J Ophthalmol 1999;127:230-3.
7. Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu SM, Ahmadi MA. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 2003; 98:504-7.
8. Skolnick CA, Doughman DJ. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere). Eye Contact Lens 2003; 29:134-5.
9. Hopen G, Mondino BJ, Johnson BL, Chervenick PA. Corneal toxicity with systemic cytarabine. Am J Ophthalmol 1981;91:500-4.
10. Khaw PT, Sherwood MB, MacKay SL, Rossi MJ, Schultz G. Fiveminute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. Arch Ophthalmol 1992;110:1150-4.
11. Margileth DA, Poplack DG, Pizzo PA, Leventhal BG. Blindness during remission in two patients with acute lymphoblastic leukemia: A possible complication of multimodality therapy. Cancer 1977; 39:58-61.
12. Shapiro MS, Thoft RA, Friend J, Parrish RK, Gressel MG. 5-Fluorouracil toxicity to the ocular surface epithelium. Invest Ophthalmol Vis Sci 1985;26:580-3.
13. Sato Y, Morita M, Takahashi HO, Watanabe N, Kirikae I. Combined surgery, radiotherapy, and regional chemotherapy in carcinoma of the paranasal sinuses. Cancer 1970;25:571-9.
14. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-9.
15. Ferraresi V, Milella M, Vaccaro A, D'Ottavio AM, Papaldo P, Nistico C, ThorelMF, Marsella A, Carpino A, Giannarelli D, Terzoli E, Cognetti F. Toxicity and activity of docetaxel in anthracyclinepretreated breast cancer patients: A phase II study. Am J Clin Oncol 2000;23:132-9.
16. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997;15:3149-55.
17. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000;18:2780-7.